Lassogen
Lassogen develops engineered lasso-peptide therapeutics for challenging cancer targets.
Founded
2019Lassogen develops engineered lasso-peptide therapeutics for challenging cancer targets.
Lassogen's technology centers on lasso peptides, whose interlocked lariat structure provides a stable scaffold for presenting amino-acid side chains to biological targets. The company is engineering these peptides to seek high-affinity and selective receptor binding.
Its official materials describe computational design and a DBTE workflow alongside peptide engineering. The pipeline page reports a preclinical ETBR program with preclinical-model results, including increased tumor immune-cell infiltration and stronger checkpoint-inhibitor activity in combination studies.
Source: lassogen.com
Lassogen's published pipeline places its ETBR program in preclinical development and its αvβ6, αvβ8, and αvβ6/8 integrin programs in discovery. The disclosed portfolio is therefore concentrated in early oncology research rather than a broad set of therapeutic areas or development stages.
That focus gives the company a coherent scientific thesis around tumor immunity, cell adhesion, and TGFβ signaling, while making clinical translation the key proof point for the approach. The pipeline materials describe preclinical and discovery work, not marketed medicines.
Source: lassogen.com
Lassogen is pursuing tumor mechanisms that can limit immune response or promote cancer progression: ETBR-mediated restriction of immune-cell infiltration, αvβ6-associated adhesion and TGFβ activation, and αvβ8-mediated immunosuppression. These programs point toward cancers in which current immune therapies can be less effective.
The company describes combination strategies with checkpoint inhibitors and other immunotherapies, alongside testing in cancer models. Its potential market reach depends on whether engineered lassotides can produce selective target inhibition and demonstrate useful activity across the named tumor settings.
Source: lassogen.com